Last Updated : August 2, 2019
Details
FilesGeneric Name:
Bosutinib
Project Status:
Complete
Therapeutic Area:
Chronic Myeloid Leukemia
Manufacturer:
Pfizer Canada Inc.
Brand Name:
Bosulif (RFA)
Project Line:
Reimbursement Review
Project Number:
PA0002-000
NOC Status at Filing:
Post NOC
Tumour Type:
Leukemia
Indications:
Chronic Myeloid Leukemia
Sponsor:
pCODR Provincial Advisory Group
Submission Date:
Stakeholder Input Deadline ‡:
pERC Meeting:
Notification to Implement Issued:
Recommendation Type:
N/A
Request for Advice Question:
RFA Question from the Provincial Advisory Group:
Is there evidence of clinical benefit sufficient to extend reimbursement eligibility of bosutinib “for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy” without limiting it further to those “for whom subsequent treatment with imatinib, nilotinib and dasatinib is not clinically appropriate”?
pERC Meeting:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : August 2, 2019